PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9334390-5 1997 In contrast, the D2 receptor agonist quinpirole decreased basal as well as D1 agonist-, forskolin-, and 8-bromo-cAMP-stimulated phosphorylation of DARPP-32. Quinpirole 37-47 dopamine receptor D2 Mus musculus 17-28 7737329-4 1995 The effects of apomorphine and of the coadministration of SKF 38393 and quinpirole on the conditioned fear stress were completely blocked by the dopamine D1 receptor antagonist, SCH 23390 (R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H- 3-benzazepine), and by the dopamine D2 receptor antagonist, (-)-sulpiride. Quinpirole 72-82 dopamine receptor D2 Mus musculus 282-302 9113126-4 1996 In the latter, intrastriatal injection of D2 antisense blocked the contralateral rotational behavior induced by the parenteral administration of the D2 dopamine receptor agonist quinpirole. Quinpirole 178-188 dopamine receptor D2 Mus musculus 149-169 8577369-2 1995 Quinpirole (1-1000 nM), a D2 receptor agonist, caused a concentration-dependent increase in [Ca2+]i. Quinpirole 0-10 dopamine receptor D2 Mus musculus 26-37 8577369-3 1995 Haloperidol, a preferential D2 receptor antagonist, completely blocked this [Ca2+]i response to quinpirole. Quinpirole 96-106 dopamine receptor D2 Mus musculus 28-39 1974856-4 1990 D2 receptor stimulation with quinpirole did not alter cGMP levels whereas D2 antagonism increased cGMP by 40-60% after haloperidol and by up to 100% after sulpiride. Quinpirole 29-39 dopamine receptor D2 Mus musculus 0-11 7913043-2 1994 With short-term reserpinization, the dopamine D2 receptor agonist, quinpirole (1.5 mg/kg), but not the dopamine D1 receptor agonist, SKF-38393 (15 mg/kg), increased motor activity. Quinpirole 67-77 dopamine receptor D2 Mus musculus 37-57 7913043-3 1994 The effect of quinpirole in short-term reserpinized mice was potentiated by the simultaneous administration of SKF-38393 (15 mg/kg) and was counteracted by the previous administration of the dopamine D2 receptor antagonist, raclopride (1 mg/kg), or by the simultaneous administration of NMDA (25 mg/kg) or MK-801 (0.5 mg/kg). Quinpirole 14-24 dopamine receptor D2 Mus musculus 191-211 8113958-4 1994 Administering the D2 antisense inhibited rotations induced by the D2 dopamine receptor agonists quinpirole and N-propyl-N-2-thienylethylamine-5-hydroxytetralin but did not block rotations induced by the D1 dopamine receptor agonist 1-phenyl-2,3,4,5-tetrahydro-1H-3 benzazepine-7,8-diol HCl or by the muscarinic cholinergic receptor agonist oxotremorine. Quinpirole 96-106 dopamine receptor D2 Mus musculus 66-86 1361188-2 1992 The dopamine D2 receptor agonist, quinpirole, accelerated the rate of acidification of the medium by C6 cells expressing either the short or long form of D2 receptors, D2(415) and D2(444), but not by wild-type cells that were not transfected with a D2 receptor cDNA. Quinpirole 34-44 dopamine receptor D2 Mus musculus 4-24 1361188-2 1992 The dopamine D2 receptor agonist, quinpirole, accelerated the rate of acidification of the medium by C6 cells expressing either the short or long form of D2 receptors, D2(415) and D2(444), but not by wild-type cells that were not transfected with a D2 receptor cDNA. Quinpirole 34-44 dopamine receptor D2 Mus musculus 13-24 1358635-1 1992 Continuous infusion of the dopamine D2 receptor agonist quinpirole into mice with unilateral striatal 6-hydroxydopamine lesions initially produces a supersensitive rotational behavior. Quinpirole 56-66 dopamine receptor D2 Mus musculus 27-47 7886117-3 1994 Quinpirole (0.0625-0.5 mg/kg), a D2 receptor agonist, had no effects at low doses but severely disrupted locomotion and exploration at the highest doses tested. Quinpirole 0-10 dopamine receptor D2 Mus musculus 33-44 8101360-0 1993 Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Quinpirole 59-69 dopamine receptor D2 Mus musculus 30-50 8101360-0 1993 Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Quinpirole 59-69 dopamine receptor D2 Mus musculus 80-100 8097720-3 1993 The dopamine D2 receptor agonist, quinpirole (0.5 and 1 mg/kg) and the dopamine D1 receptor agonist, SKF 38393 (20 mg/kg) impaired latent learning, but both effects were less than that of GBR-12909. Quinpirole 34-44 dopamine receptor D2 Mus musculus 4-24 1974818-0 1990 [Immunostimulating effect of D2 dopamine receptor agonist quinpirole]. Quinpirole 58-68 dopamine receptor D2 Mus musculus 29-49 1974818-1 1990 Immunostimulating activity of specific postsynaptic D2 receptor agonist quinpirole (Ly 171555) was studied in CBA mice. Quinpirole 72-82 dopamine receptor D2 Mus musculus 52-63 34921828-4 2022 Previously, we reported that repeated injection of the dopamine D2 receptor agonist quinpirole (QNP) resulted in OCD-like deficits, including perseveration in a reversal learning task. Quinpirole 84-94 dopamine receptor D2 Mus musculus 55-75 34921828-4 2022 Previously, we reported that repeated injection of the dopamine D2 receptor agonist quinpirole (QNP) resulted in OCD-like deficits, including perseveration in a reversal learning task. Quinpirole 96-99 dopamine receptor D2 Mus musculus 55-75 34734506-9 2021 Nasal administration of quinpirole (Quin, a dopamine D2 receptor agonist, 3 mg/kg) improved olfactory function in mice, inhibited the expression of toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signalings and the levels of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the olfactory bulb. Quinpirole 24-34 dopamine receptor D2 Mus musculus 44-64 34737042-10 2021 Our results suggested: (1) NO and dopamine D2 receptor mechanisms affect anxiety and memory in PD mice; (2) L-NAME reversed anxiogenic and memory-improvement effect induced by sulpiride; (3) Anxiolytic and amnesic effects induced by quinpirole reversed by L-arginine; (4) There is a synergistic effect between dopamine D2 receptor and NO systems on the modulation of anxiety and memory. Quinpirole 233-243 dopamine receptor D2 Mus musculus 34-54 34737042-10 2021 Our results suggested: (1) NO and dopamine D2 receptor mechanisms affect anxiety and memory in PD mice; (2) L-NAME reversed anxiogenic and memory-improvement effect induced by sulpiride; (3) Anxiolytic and amnesic effects induced by quinpirole reversed by L-arginine; (4) There is a synergistic effect between dopamine D2 receptor and NO systems on the modulation of anxiety and memory. Quinpirole 233-243 dopamine receptor D2 Mus musculus 310-330 34624383-5 2021 Quinpirole (a dopamine D2 receptor agonist) improved olfactory function in mice, ameliorated apoptosis injury in the olfactory bulb but not in the olfactory mucosa, and inhibited the internalization of GluR2-containing AMPA receptor in vitro and in vivo. Quinpirole 0-10 dopamine receptor D2 Mus musculus 14-34 34734506-9 2021 Nasal administration of quinpirole (Quin, a dopamine D2 receptor agonist, 3 mg/kg) improved olfactory function in mice, inhibited the expression of toll-like receptor 4 (TLR4)/nuclear factor-kappaB (NF-kappaB) signalings and the levels of tumor necrosis factor-alpha, interleukin (IL)-1beta and IL-6 in the olfactory bulb. Quinpirole 36-40 dopamine receptor D2 Mus musculus 44-64 33850083-7 2021 D2L KO mice also displayed markedly enhanced AIMs in response to chronic treatment with quinpirole, a preferential D2R agonist. Quinpirole 88-98 dopamine receptor D2 Mus musculus 115-118 2571943-3 1989 (2) The selective D-2 receptor agonists pergolide and quinpirole inhibited the 3H-NPA binding biphasically at low doses, indicating that these DA receptor agonists have high affinities for a subfraction (10 to 30%) of the NPA binding sites. Quinpirole 54-64 dopamine receptor D2 Mus musculus 18-30 34408150-5 2021 Moreover, prolonged exposure to the D2 receptor agonist, quinpirole, rescues many of the alterations induced by alpha-synuclein overexpression. Quinpirole 57-67 dopamine receptor D2 Mus musculus 36-47 2575999-2 1989 The selective D-2 receptor agonists, quinpirole and LY 163502, and the mixed D-1/D-2 agonist, apomorphine, induced a dose-dependent hypothermia, whereas the selective D-1 receptor agonists, SK&F 81297, SK&F 38393 and SK&F 75670, induced hyperthermia. Quinpirole 37-47 dopamine receptor D2 Mus musculus 14-26 2902647-5 1988 Similarly, in mice pretreated with the D2 receptor antagonist sulpiride before EEDQ and again challenged with the D1 and D2 agonists 24 hours later, the rotational response to SKF 38393 was still inhibited but the response to quinpirole was no longer inhibited. Quinpirole 226-236 dopamine receptor D2 Mus musculus 39-50 32935231-8 2021 The treatment with dopamine 2 receptor (D2R) agonist quinpirole recovered striatal LTD and improved the impaired behavioral habituation in PD 45 adult PRS mice. Quinpirole 53-63 dopamine receptor D2 Mus musculus 19-38 33476687-8 2021 The striatal ChIs in the Drd2 ChKO mice showed an increased firing frequency and impaired quinpirole-induced inhibition, suggesting a reduced D2R function on the ChIs. Quinpirole 90-100 dopamine receptor D2 Mus musculus 25-29 33430188-7 2021 Quinpirole administration regulated D2R expression and significantly reduced glial cell-induced neuroinflammation via the D2R/Akt/glycogen synthase kinase 3 beta (GSK3-beta) signaling pathway after TBI. Quinpirole 0-10 dopamine receptor D2 Mus musculus 36-39 33430188-7 2021 Quinpirole administration regulated D2R expression and significantly reduced glial cell-induced neuroinflammation via the D2R/Akt/glycogen synthase kinase 3 beta (GSK3-beta) signaling pathway after TBI. Quinpirole 0-10 dopamine receptor D2 Mus musculus 122-125 33430188-9 2021 Additionally, our in vitro results confirmed that quinpirole reversed the microglial condition media complex-mediated deleterious effects and regulated D2R levels in HT22 cells. Quinpirole 50-60 dopamine receptor D2 Mus musculus 152-155 33430188-10 2021 This study showed that quinpirole administration after TBI reduced secondary brain injury-induced glial cell activation and neuroinflammation via regulation of the D2R/Akt/GSK3-beta signaling pathways. Quinpirole 23-33 dopamine receptor D2 Mus musculus 164-167 32935231-8 2021 The treatment with dopamine 2 receptor (D2R) agonist quinpirole recovered striatal LTD and improved the impaired behavioral habituation in PD 45 adult PRS mice. Quinpirole 53-63 dopamine receptor D2 Mus musculus 40-43 33339892-6 2020 injection of both the dopamine D2 receptor agonist quinpirole and the antagonist l-sulpiride increased plasma glucose levels. Quinpirole 51-61 dopamine receptor D2 Mus musculus 22-42 32682848-8 2020 Moreover, by using selective antagonists at D2-like receptors (encompassing the D2, D3, and D4 subtypes), we found that the D2 and D3 receptor subtypes participate in the quinpirole depressant inhibitory effects of pathways mediating PAD. Quinpirole 171-181 dopamine receptor D2 Mus musculus 124-142 30200997-7 2018 RESULTS: We showed that the selective Drd2 agonist quinpirole suppressed inflammation in the midbrain of wild-type mice, but not in alpha-Syn-overexpressed mice. Quinpirole 51-61 dopamine receptor D2 Mus musculus 38-42 31233824-5 2019 Stimulation of D2 receptors with the selective D2 receptor agonist quinpirole decreased expression of miRNA-143 in a time-dependent manner. Quinpirole 67-77 dopamine receptor D2 Mus musculus 15-26 31233824-7 2019 We further demonstrated that miRNA-143 directly targeted to the 3" un-translated region of neuregulin-1 (NRG1) mRNA to reduce protein expression of NRG1 in HT-22 cells and that administration of the D2 receptor agonist quinpirole to mice enhanced expression of NRG1 in PFC. Quinpirole 219-229 dopamine receptor D2 Mus musculus 199-210 32655360-3 2020 Here, we investigated how excessive D2R-DISC1 complex formation induced by D2R agonist quinpirole affects neurite growth and dendritic spines in striatal neurons. Quinpirole 87-97 dopamine receptor D2 Mus musculus 36-39 32655360-3 2020 Here, we investigated how excessive D2R-DISC1 complex formation induced by D2R agonist quinpirole affects neurite growth and dendritic spines in striatal neurons. Quinpirole 87-97 dopamine receptor D2 Mus musculus 75-78 32077679-6 2020 Photolysis of CyHQ-sulpiride rapidly blocked synaptic activity, enabling measurement of the unbinding rates of dopamine and quinpirole, a D2 receptor agonist. Quinpirole 124-134 dopamine receptor D2 Mus musculus 138-149 30245624-10 2018 However, under stimulation of D2R by quinpirole, LTP was enhanced in hippocampal slices incubated with TAT-D2pep, supporting the notion that TAT-D2pep acts in a dopamine-dependent manner and acts as synaptic enhancer. Quinpirole 37-47 dopamine receptor D2 Mus musculus 30-33 26220941-11 2015 D2-dopamine receptors exhibited a change in the valence in DRD mice with an increase in adenylate cyclase activity and blunted behavioural responses after challenge with the D2-dopamine receptor agonist quinpirole. Quinpirole 203-213 dopamine receptor D2 Mus musculus 0-20 27498335-5 2016 The specific D2 receptor agonist Quinpirole, added in low concentrations, caused a significant reduction of the A2a-induced cAMP formation, which was not observed in the control mouse. Quinpirole 33-43 dopamine receptor D2 Mus musculus 13-24 27498335-6 2016 Furthermore, the D1 receptor induced cAMP synthesis was significantly higher in control compared to "weaver" striatum, which was more efficiently downregulated by D2 receptor agonist Quinpirole. Quinpirole 183-193 dopamine receptor D2 Mus musculus 163-174 27041647-5 2016 Pre-training intra-mPFC administration of SKF 38393, D1 receptor agonist and quinpirol D2 receptor agonist, alone did not affect memory acquisition. Quinpirole 77-86 dopamine receptor D2 Mus musculus 87-98 26498506-11 2016 Notably, the CB1R-dependent inhibition of synaptic activity was restored either by amphetamine or after chronic treatment with the D2 dopamine receptor agonist quinpirole. Quinpirole 160-170 dopamine receptor D2 Mus musculus 131-151 24753432-4 2014 Using whole cell electrophysiological recordings in hippocampal slice preparations, we provide evidence that unlike in basal ganglia, activation of DRD2 by the selective agonist, quinpirole, induces a long-lasting increase in excitability of hilar mossy cells, which can be blocked by the DRD2 antagonist raclopride. Quinpirole 179-189 dopamine receptor D2 Mus musculus 148-152 26251254-10 2015 DRD2 activation by quinpirole and ropinirole ameliorated neurological outcome, brain edema, interleukin-1beta, and monocyte chemoattractant protein-1 expression, as well as microglia/macrophages activation, in the perihematomal region. Quinpirole 19-29 dopamine receptor D2 Mus musculus 0-4 25721394-6 2015 Finally, we found that the locomotor activation induced by the D2 dopamine receptor agonist quinpirole, but not by the full D1 dopamine receptor agonist SKF-82958, was increased in TAAR1-KO mice. Quinpirole 92-102 dopamine receptor D2 Mus musculus 63-83 24753432-4 2014 Using whole cell electrophysiological recordings in hippocampal slice preparations, we provide evidence that unlike in basal ganglia, activation of DRD2 by the selective agonist, quinpirole, induces a long-lasting increase in excitability of hilar mossy cells, which can be blocked by the DRD2 antagonist raclopride. Quinpirole 179-189 dopamine receptor D2 Mus musculus 289-293 21195752-7 2011 However, in both dopamine-depleted rats and DJ-1-/- mice the D2 receptor agonist quinpirole inhibited a greater fraction of HVA Ca2+ current than in the respective controls. Quinpirole 81-91 dopamine receptor D2 Mus musculus 61-72 23242137-8 2013 Furthermore, treatment of wild-type mice with the selective DRD2 agonist quinpirole increased resistance of the nigral dopaminergic neurons to MPTP through partial suppression of inflammation. Quinpirole 73-83 dopamine receptor D2 Mus musculus 60-64 24616667-8 2014 Local D2 receptor activation by quinpirole enhanced pyramidal neuron spike firing rate without changes in spike firing pattern. Quinpirole 32-42 dopamine receptor D2 Mus musculus 6-17 21669258-7 2011 Spontaneous activity of dopamine neurons was recorded in midbrain slices, and concentration-dependent effects of the dopamine D2 receptor agonist, quinpirole, was compared between wild-type and A(2A) knockout mice. Quinpirole 147-157 dopamine receptor D2 Mus musculus 117-137 21242252-7 2011 In histamine deficient mice the wake-promoting action of the D2 receptor agonist quinpirole (1 mg kg-1, I.P.) Quinpirole 81-91 dopamine receptor D2 Mus musculus 61-72 20080963-6 2010 Stimulation of D2R by the D2R agonist quinpirole suppressed the leptin-induced STAT3 phosphorylation and nuclear trans-localization of phospho-STAT3 in the hypothalamus of wild type mice. Quinpirole 38-48 dopamine receptor D2 Mus musculus 15-18 20080963-6 2010 Stimulation of D2R by the D2R agonist quinpirole suppressed the leptin-induced STAT3 phosphorylation and nuclear trans-localization of phospho-STAT3 in the hypothalamus of wild type mice. Quinpirole 38-48 dopamine receptor D2 Mus musculus 26-29 18644366-12 2008 Quinpirole, a dopamine D2 receptor agonist, showed significant suppression of locomotor activity at the dose that inhibited marble-burying behavior. Quinpirole 0-10 dopamine receptor D2 Mus musculus 14-34 19667187-6 2009 The introduction of the R1441C mutation also impairs dopamine D2 receptor function, as suggested by decreased responses of KI mice in locomotor activity to the inhibitory effect of a D2 receptor agonist, quinpirole. Quinpirole 204-214 dopamine receptor D2 Mus musculus 53-73 19667187-6 2009 The introduction of the R1441C mutation also impairs dopamine D2 receptor function, as suggested by decreased responses of KI mice in locomotor activity to the inhibitory effect of a D2 receptor agonist, quinpirole. Quinpirole 204-214 dopamine receptor D2 Mus musculus 62-73 16723261-4 2006 administration of the dopamine D1 receptor agonist (SKF38393), dopamine D2 receptor agonist (quinpirole) and dopamine D2 receptor antagonist (sulpiride) not only reversed the effect of pre-training morphine treatment, but also increased this action of the drug. Quinpirole 93-103 dopamine receptor D2 Mus musculus 63-83 18246449-5 2008 The dopamine receptor D2/3 agonist quinpirole rescued LTD in DJ-1-/- mice, suggesting a role for impaired dopaminergic signaling in the hippocampal LTD deficit. Quinpirole 35-45 dopamine receptor D2 Mus musculus 4-26 18606403-5 2008 administration of the dopamine D1 receptor agonist SKF38393 and the dopamine D2 receptor agonist quinpirole by themselves and in combination with ineffective doses of lithium (0.3, 0.6 and 1.25 mg/kg) reversed the decrease of the step-down latency induced by post-training lithium. Quinpirole 97-107 dopamine receptor D2 Mus musculus 68-88 18003826-5 2007 Inhibition of dopamine neuron firing by pretreatment with quinpirole, a dopamine D2-receptor agonist, blocked both cocaine- and fluoxetine-induced CPP in DD mice. Quinpirole 58-68 dopamine receptor D2 Mus musculus 72-92 16905556-6 2006 Importantly, abnormalities in both short-term and long-term plasticity can be reversed by the introduction of a D2 dopamine receptor agonist (Quinpirole), suggesting that alterations in dopaminergic signalling may underlie early cognitive dysfunction in HD. Quinpirole 142-152 dopamine receptor D2 Mus musculus 112-132 17141847-6 2006 The D2 receptor agonist, quinpirole, depressed these behaviors entirely, while the D1 antagonist, SCH23390, inhibited the enhancement of these behaviors by L-DOPA. Quinpirole 25-35 dopamine receptor D2 Mus musculus 4-15 16893530-5 2006 RESULTS: We report here that Nur77-deficient mice display enhanced spontaneous locomotor activity, greater sensitivity to a small dose of the dopamine D2 receptor agonist quinpirole acting mainly at autoreceptor sites, and higher levels of the dopamine metabolite DOPAC relative to wild-type mice. Quinpirole 171-181 dopamine receptor D2 Mus musculus 142-162 16688761-3 2006 Dopamine, SKF 38393 (D1 receptor agonist), and quinpirole (D2 receptor agonist) decreased the level of [(3)H]-thymidine incorporation. Quinpirole 47-57 dopamine receptor D2 Mus musculus 59-70 15857393-3 2005 The D2 receptor agonist quinpirole enhanced the coprecipitation of D2 and EGF receptors in NS20Y cells, suggesting that D2 receptor activation induced the formation of a macromolecular signaling complex that includes both receptors. Quinpirole 24-34 dopamine receptor D2 Mus musculus 4-15 15857393-2 2005 In contrast, ectopically expressed D2 receptor or endogenous D2-like receptor activation of ERKs in NS20Y neuroblastoma cells, which express little or no PDGF receptor, or in rat neostriatal neurons was largely dependent on transactivation of the epidermal growth factor (EGF) receptor, as demonstrated using the EGF receptor inhibitor AG 1478 and by quinpirole-induced phosphorylation of the EGF receptor. Quinpirole 351-361 dopamine receptor D2 Mus musculus 35-46 15857393-3 2005 The D2 receptor agonist quinpirole enhanced the coprecipitation of D2 and EGF receptors in NS20Y cells, suggesting that D2 receptor activation induced the formation of a macromolecular signaling complex that includes both receptors. Quinpirole 24-34 dopamine receptor D2 Mus musculus 120-131 15489038-4 2004 Accordingly, the inhibitory effects of the DA D2 receptor agonist quinpirole (10 microM) on GABA(A)-mediated spontaneous inhibitory postsynaptic currents (IPSCs)correlate with the total number of D2 receptor sites in the striatum, irrespective of the specific receptor isoform expressed. Quinpirole 66-76 dopamine receptor D2 Mus musculus 46-57 15489038-4 2004 Accordingly, the inhibitory effects of the DA D2 receptor agonist quinpirole (10 microM) on GABA(A)-mediated spontaneous inhibitory postsynaptic currents (IPSCs)correlate with the total number of D2 receptor sites in the striatum, irrespective of the specific receptor isoform expressed. Quinpirole 66-76 dopamine receptor D2 Mus musculus 196-207 15489038-5 2004 In contrast, glutamate-mediated spontaneous excitatory postsynaptic currents (EPSCs) were significantly inhibited by quinpirole only when the total number of D2 receptor sites, normally composed by both D2L and D2S receptors in a ratio favoring the D2L isoform, was modified to express only the D2S isoform at higher than normal levels. Quinpirole 117-127 dopamine receptor D2 Mus musculus 158-169 14751293-6 2004 Co-administration of CGS21680 and quinpirole (D2 receptor agonist) attenuated the expression of zif/268 mRNA in dorsal striatum but not in motor cortex, indicating that the cortical response is dopamine-D2-receptor-independent. Quinpirole 34-44 dopamine receptor D2 Mus musculus 46-57 14751293-6 2004 Co-administration of CGS21680 and quinpirole (D2 receptor agonist) attenuated the expression of zif/268 mRNA in dorsal striatum but not in motor cortex, indicating that the cortical response is dopamine-D2-receptor-independent. Quinpirole 34-44 dopamine receptor D2 Mus musculus 194-214 12716422-10 2003 The D2/D3 receptor agonist quinpirole inhibited impulse-dependent DA release with a lower EC50 value in homozygous mice (12 nm) compared with wild-types (34 nm), indicating the compensatory presence of functionally supersensitive release-regulating autoreceptors. Quinpirole 27-37 dopamine receptor D2 Mus musculus 4-18 12699776-6 2003 Bath perfusion of dopamine or the D(2) dopamine receptor agonist quinpirole restored LTD in G93A+ mice. Quinpirole 65-75 dopamine receptor D2 Mus musculus 34-56 12466426-7 2002 Quinpirole, a D2 receptor agonist alone, produced small reductions of NMDA currents. Quinpirole 0-10 dopamine receptor D2 Mus musculus 14-25 12867509-8 2003 Both isoforms of D2 receptor, D2L and D2S, were very likely involved in this inhibitory action, as revealed by the electrophysiological analysis of the effect of the DA D2-like receptor agonist quinpirole in two distinct mutants lacking D2L receptors and expressing variable contents of D2S receptors. Quinpirole 194-204 dopamine receptor D2 Mus musculus 17-28 12651945-4 2003 Incubation of striatal slices from wild-type mice with quinpirole, a dopamine D2 receptor agonist, decreased the state of phosphorylation of TH at Ser-40 and its enzymatic activity. Quinpirole 55-65 dopamine receptor D2 Mus musculus 69-89 12242090-7 2002 The dopamine D2 receptor agonist, quinpirole (0.1, 0.3 and 0.5 mg/kg), increased jumping, while it decreased diarrhoea in mice. Quinpirole 34-44 dopamine receptor D2 Mus musculus 4-24 12358756-5 2002 Long-term 18 h treatment with the D2 receptor agonist, quinpirole, resulted in a two-fold enhancement of forskolin-stimulated cyclic AMP accumulation. Quinpirole 55-65 dopamine receptor D2 Mus musculus 34-45 12236635-3 2002 The D2 dopamine receptor agonist, quinpirole (0.01, 0.02 and 0.03 mg/kg), but not the D2 dopamine receptor antagonist, sulpiride (12.5, 25 and 50 mg/kg), increased morphine antinociception in morphine non pre-exposed mice. Quinpirole 34-44 dopamine receptor D2 Mus musculus 4-24 11787947-4 2001 [3H]Quinpirole binding was decreased in D2 receptor-deficient mice to 3% of that observed in wild-type controls indicating that [3H]quinpirole binding is associated with the D2 dopamine receptors. Quinpirole 4-14 dopamine receptor D2 Mus musculus 40-51 11787947-4 2001 [3H]Quinpirole binding was decreased in D2 receptor-deficient mice to 3% of that observed in wild-type controls indicating that [3H]quinpirole binding is associated with the D2 dopamine receptors. Quinpirole 132-142 dopamine receptor D2 Mus musculus 40-51 11787947-12 2001 These data suggest that [3H]Ro-41-1049 labels multiple sites and that MAOIs modulate [3H]quinpirole binding to the D2 receptor via interactions at a novel, non-MAO binding site with MAO(A)-like pharmacology. Quinpirole 89-99 dopamine receptor D2 Mus musculus 115-126 11054779-6 2000 We definitively mapped a QTL on Chromosome (Chr) 9 linked to the D(2) dopamine receptor gene, Drd2, for hypothermic sensitivity to quinpirole, and identify a suggestive QTL in the same chromosomal region for tolerance to quinpirole after repeated treatments. Quinpirole 131-141 dopamine receptor D2 Mus musculus 65-87 11054779-6 2000 We definitively mapped a QTL on Chromosome (Chr) 9 linked to the D(2) dopamine receptor gene, Drd2, for hypothermic sensitivity to quinpirole, and identify a suggestive QTL in the same chromosomal region for tolerance to quinpirole after repeated treatments. Quinpirole 131-141 dopamine receptor D2 Mus musculus 94-98 11054779-8 2000 Our results indicate that genetic differences in quinpirole sensitivity and tolerance are associated with QTLs near Drd2, and that baseline locomotor activity is associated with a suggestive QTL in proximity to the dopamine transporter gene Dat1. Quinpirole 49-59 dopamine receptor D2 Mus musculus 116-120